Clinical trials: Geriatric Disorder
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva and gemcitabine, and of gemcitabine monotherapy, as first line treatment of elderly patients, or patients with ECOG performance status of…
- Trial name
- NCT00940875
- Testing
- erlotinib [Tarceva], gemcitabine
- Where
- 17 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on…
- Conditions
- COVID-19, Chronic Bronchitis, Copd
- Trial name
- NCT05075057
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Hemophilia
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in…
- Trial name
- ATLAS-NEO (NCT05662319)
- Testing
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 50 sites in United States, Canada and 15 more
- Volunteers
- 91 people
- Sponsor
- Sanofi
Influenza
Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset) following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs, in healthy…
- Trial name
- NCT00306527
- Testing
- Cell culture derived influenza vaccine, egg-derived influenza subunit vaccine
- Where
- 5 sites in Poland
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Asthma
A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)
A study to determine the efficacy of MK0476 in the Treatment of Asthmatic Patients Aged 2 to 5 Years.
- Trial name
- NCT00700661
- Testing
- montelukast
- Volunteers
- 500 people
- Sponsor
- Organon and Co
Allergic Diseases
Trial of JYB1904 Injection in Adolescent Participants
This Phase Ib Trial is Meant to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants With Allergic Diseases.
- Trial name
- NCT07513857
- Testing
- JYB1904
- Volunteers
- 12 people
- Sponsor
- Jemincare
Sarcopenia
Amino Acid Bioavailability in Healthy Elderly After Intake of an Oral Nutritional Supplement
In this study healthy older adults are requested to consume 4 different high-protein nutritional supplements. Each subject will visit the site 4 times and at every visit they will consume 1 of the 4 products after which a series…
- Trial name
- ArenA (NCT02013466)
- Testing
- Bolus ONS A, Bolus ONS B, Bolus ONS C
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Alzheimer Disease
Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
- Trial name
- NCT04074837
- Testing
- NNI-362
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Neuronascent, Inc.
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Volunteers
- 356 people
- Sponsor
- Sanofi
Japanese Encephalitis Virus Disease
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
- Trial name
- NCT06680128
- Testing
- GBP560-A, GBP560-B, IXIARO
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Periodontal Disease
Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age
The purpose of this study is to learn about the interactions of markers of type 2 diabetes (T2DM) and periodontitis (PD). Study VPE00001 is a multi-center cross-sectional study.
- Trial name
- NCT06582056
- Testing
- Investigational Procedure
- Where
- 4 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Migraine
A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.
This is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy…
- Trial name
- NCT05046522
- Testing
- Palmitoylethanolamide sold as Levagen +
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- RDC Clinical Pty Ltd
Influenza, Swine-origin A/H1N1 Influenza
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00954798
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated)
- Where
- 6 sites in France
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies (Healthy Volunteers)
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after post-exposure prophylaxis (PEP) vaccination, and to confirm its satisfying safety profile in the…
- Trial name
- NCT07055893
- Testing
- Rabies vaccine, Verorab®
- Where
- Pakistan
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
Precursor Cell Lymphoblastic Leukemia-lymphoma
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with…
- Trial name
- NCT03888534
- Testing
- Ixazomib
- Where
- 7 sites in United States, Spain
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatitis A
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi.
- Trial name
- NCT00197249
- Testing
- Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above.
- Trial name
- NCT07327398
- Testing
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Elderly Patients, Polypathology
Personalized Digital Remote Monitoring for Elderly Patients
Objective This clinical investigation aims to evaluate whether the EPOCA Remote Monitoring System (RMS) enhances care for elderly patients with multiple chronic conditions and reduces unplanned hospitalizations.
- Conditions
- Elderly Patients, Polypathology, Multiple Chronic Conditions
- Trial name
- EPOCARE (NCT06845917)
- Testing
- Remote Patient Monitoring system
- Volunteers
- 700 people
- Sponsor
- EPOCA U&I
Dengue Fever
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
- Trial name
- NCT04313244
- Testing
- 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV)
- Where
- 4 sites in Thailand
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Takeda